图书馆订阅: Guest
真核基因表达评论综述™

每年出版 6 

ISSN 打印: 1045-4403

ISSN 在线: 2162-6502

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.6 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.2 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00058 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.33 SJR: 0.345 SNIP: 0.46 CiteScore™:: 2.5 H-Index: 67

Indexed in

Diverse Signaling Pathways and Current Status of Molecular Targeted Treatments for Hepatocellular Carcinoma

卷 27, 册 4, 2017, pp. 373-385
DOI: 10.1615/CritRevEukaryotGeneExpr.2017021006
Get accessGet access

摘要

Hepatocellular carcinoma (HCC) is one of the leading causes of death associated with cancer. Various molecular mechanisms are involved in HCC development. Alterations in these molecular mechanisms include chromosomal instability, gene mutations, and variations in protein expressions. A number of cell signaling pathways that are associated with the occurrence of apoptosis, cell proliferation, and angiogenesis provide new prospects for the development of HCC treatments. Newly designed, potential therapeutic regimens target specific receptors, kinases, and vital proteins. Sorafenib is the only FDA-approved drug for HCC treatment, and it has been found that the complex genomic aberrations in HCC can be overcome using combination therapy. For example, therapeutic benefits have been gained using sorafenib with doxorubicin, oxaliplatin, cisplatin, and monoclonal antibodies. In addition, elumetinib, carbozantinib, and refametinib may be effective when used in combination with sorafenib. Drugs that target several signaling pathways have shown promising results in phase 3 clinical trials, and clinical studies using these drugs have changed the management strategy for HCC, particularly with the use of combination therapeutic regimens. Such research has improved the current standards of care and influenced clinical decision making.

对本文的引用
  1. Allen Rebecca, Li Daneng, Hepatocellular Carcinoma, in Oncology in the Precision Medicine Era, 2020. Crossref

  2. Ren Feng, Wu Kaixuan, Yang Yun, Yang Yingying, Wang Yuxia, Li Jian, Dandelion Polysaccharide Exerts Anti-Angiogenesis Effect on Hepatocellular Carcinoma by Regulating VEGF/HIF-1α Expression, Frontiers in Pharmacology, 11, 2020. Crossref

  3. Zhong Xiao‑Zhu , Deng Yun , Chen Gang , Yang Hong , Investigation of the clinical significance and molecular mechanism of miR‑21‑5p in hepatocellular carcinoma: A systematic review based on 24 studies and bioinformatics investigation, Oncology Letters, 2018. Crossref

  4. Akhtar Muhammad Furqan, Saleem Ammara, Rasul Azhar, Faran Ashraf Baig Mirza Muhammad, Bin-Jumah May, Abdel Daim Mohamed M., Anticancer natural medicines: An overview of cell signaling and other targets of anticancer phytochemicals, European Journal of Pharmacology, 888, 2020. Crossref

  5. Liu Zhao, Sun Jiuzheng, Li Chuanzhi, Xu Liyou, Liu Jun, MKL1 regulates hepatocellular carcinoma cell proliferation, migration and apoptosis via the COMPASS complex and NF-κB signaling, BMC Cancer, 21, 1, 2021. Crossref

  6. Saleem Mohammad, Schini-Kerth Valerie B., Hussain Khalid, Khalid Syed H., Asif Muhammad, Alhosin Mahmoud, Akhtar Muhammad F., Ahmad Bashir, Raza Atif, Mahrukh , Molecular Mechanisms Responsible for In Vitro Cytotoxic Attributes of Conyza bonariensis Extract against Lymphoblastic Leukaemia Jurkat Cells, Anti-Cancer Agents in Medicinal Chemistry, 22, 9, 2022. Crossref

Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集 订购及政策 Begell House 联系我们 Language English 中文 Русский Português German French Spain